BidaskClub Downgrades Amarin Corporation PLC (NASDAQ:AMRN) to Hold

BidaskClub cut shares of Amarin Corporation PLC (NASDAQ:AMRN) from a buy rating to a hold rating in a research report released on Saturday, August 5th.

AMRN has been the subject of several other research reports. HC Wainwright reaffirmed a buy rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Wednesday, June 28th. Jefferies Group LLC lifted their price objective on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the company a buy rating in a research note on Friday, June 30th. Zacks Investment Research lowered shares of Amarin Corporation PLC from a buy rating to a hold rating in a research report on Monday, May 8th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of Amarin Corporation PLC and gave the stock a buy rating in a research report on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $7.35.

Shares of Amarin Corporation PLC (AMRN) remained flat at $3.04 during midday trading on Friday. The company’s stock had a trading volume of 1,588,346 shares. The stock’s 50 day moving average price is $3.80 and its 200-day moving average price is $3.32. Amarin Corporation PLC has a 1-year low of $2.56 and a 1-year high of $4.47. The company’s market cap is $823.21 million.

Amarin Corporation PLC (NASDAQ:AMRN) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to analyst estimates of $40.35 million. The company’s quarterly revenue was up 37.0% on a year-over-year basis. During the same period last year, the business earned ($0.07) EPS. On average, equities research analysts anticipate that Amarin Corporation PLC will post ($0.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades Amarin Corporation PLC (NASDAQ:AMRN) to Hold” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/amarin-corporation-plc-nasdaqamrn-lowered-to-hold-at-bidaskclub-updated.html.

In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $4.00, for a total value of $1,231,644.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.72% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its position in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. Perkins Capital Management Inc. purchased a new position in Amarin Corporation PLC during the first quarter worth approximately $110,000. JPMorgan Chase & Co. raised its position in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 7,580 shares during the period. Westside Investment Management Inc. raised its position in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 300 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 1,032 shares during the last quarter. Hedge funds and other institutional investors own 37.60% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

What are top analysts saying about Amarin Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amarin Corporation PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit